Sunday 15 November 2026
Export DYAI’s income statement to Excel — free account
Dyadic International Inc.
DYAIDyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.
- Revenue
- −61.4%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +0.80%
Quarter to September 2026, against a year earlier
0.33
0.02
−5.71%
Follow DYAI
Alert me
Dyadic International Inc. (DYAI) P/E ratio
Dyadic International Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 86.5× (April 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 86.5×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DYAI Dyadic International Inc. | n/m |
| MCRB Seres Therapeutics, Inc. compare | n/m |
| ALGS Aligos Therapeutics, Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| QNTM Quantum Biopharma Ltd. compare | n/m |
| PLUR Pluri Inc. compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| Biotechnology industry median | 11.4× |
| Healthcare sector median | 25.3× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)